Immunotoxin Global Market Report 2024

The immunotoxin market size has grown strongly in recent years. It will grow from $55.94 billion in 2023 to $60.97 billion in 2024 at a compound annual growth rate (CAGR) of 9%. The growth during the historic period can be credited to the discovery of target antigens, advancements in monoclonal antibody technology, preclinical efficacy studies, clinical trials and regulatory approval, and the identification of resistance mechanisms.

The immunotoxin market size is expected to see strong growth in the next few years. It will grow to $86.29 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the rising incidence of cancer, increased demand for natural and organic products, expansion of the cosmetic industry, growth in R&D funding, and improvements in healthcare infrastructure. Major trends expected during the forecast period include the precision medicine approach, improved targeting strategies, multifunctional immunotoxins, combination therapies, and advancements in monoclonal antibody technology.

The rising incidence of breast cancer is anticipated to drive the growth of the immunotoxin market. Breast cancer, a type of cancer that develops in breast cells, is becoming more common due to factors such as improved screening, lifestyle changes, and increased life expectancy. Immunotoxins assist in breast cancer treatment by specifically targeting and killing cancer cells while sparing healthy cells, thereby reducing the side effects commonly associated with traditional chemotherapy. For example, according to the American Cancer Society, a US-based non-profit organization, there were 300,590 new cases of breast cancer reported in 2023, an increase from the 290,560 cases reported in 2022. Thus, the rising incidence of breast cancer is fueling the expansion of the immunotoxin market.

Leading companies in the immunotoxin market are concentrating on developing antibody-drug conjugates (ADCs) to improve the precision and effectiveness of cancer treatments. ADCs are biopharmaceuticals designed for targeted cancer therapy, consisting of an antibody linked to a cytotoxic drug, which allows for the targeted delivery of the drug to cancer cells expressing a specific antigen. For instance, in April 2024, Pfizer Inc., a US-based pharmaceutical company, and Genmab A/S, a Denmark-based biotechnology company, received full U.S. Food and Drug Administration (FDA) approval for TIVDAK, an antibody-drug conjugate designed to treat patients with metastatic or recurrent cervical cancer. TIVDAK's toxic payload, monomethyl auristatin E, is a microtubule-disrupting agent that induces cell death. This novel mechanism contributes to its effectiveness in cancer treatment. TIVDAK demonstrated statistically significant improvements in overall survival, making it a promising option for patients with recurrent or metastatic cervical cancer.

In November 2021, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Trillium Therapeutics for $2.22 billion. This acquisition aims to strengthen Pfizer's position in oncology by adding next-generation immunotherapies for hematological malignancies to its portfolio. The deal will enhance Pfizer's portfolio with potentially best-in-class compounds, accelerating advancements in cancer treatment. Trillium Therapeutics is a Canada-based immuno-oncology company focused on the development and research of immunotoxins.

Major companies operating in the immunotoxin market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Thermo Fisher Scientific Inc., AstraZeneca plc, Merck KGaA, BioNTech SE, Ipsen Pharma, Seagen Inc., Orion Corporation, GenScript, Cytek Biosciences, MacroGenics Inc., Sutro Biopharma Inc., Sorrento Therapeutics Inc., Innate Pharma Inc., Cayman Chemical, ImmunoGen Inc., Mersana Therapeutics, Molecular Templates Inc., Celldex Therapeutics, CytImmune Sciences Inc., Enzo Life Sciences Inc.

North America was the largest region in the immunotoxin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunotoxin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the immunotoxin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immunotoxins are bioengineered proteins that combine an antibody or antibody fragment with a toxin to specifically target and destroy certain cells, such as cancer cells. The antibody segment of the immunotoxin attaches to a specific antigen on the surface of the target cell, delivering the toxin directly to it. Immunotoxins are crafted to avoid harming healthy cells and tissues, thereby reducing side effects compared to traditional chemotherapy.

The primary types of immunotoxins include anthrax-based toxins, diphtheria toxin (DT) and its derivatives, pseudomonas exotoxin (PE) and its derivatives, ribosome-inactivating protein-based immunotoxins, ribonuclease-based immunotoxins, among others. Anthrax-based toxins are substances produced by the bacteria that cause anthrax, a severe disease. These toxins are used in various applications, including the treatment of solid tumors, leukemias, and more, by different end users such as hospitals and clinics, cancer and radiation therapy centers, research laboratories, and others.

The immunotoxins market research report is one of a series of new reports that provides immunotoxins market statistics, including the immunotoxins industry global market size, regional shares, competitors with immunotoxins market share, detailed immunotoxins market segments, market trends, and opportunities, and any further data you may need to thrive in the immunotoxins industry. These immunotoxins market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunotoxin market consists of sales of linker molecules, expression systems, antibody or antibody fragments, and cytotoxic agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.